SLC22A13
Solute carrier family 22 member 13
Also known as: OAT10, OCTL1, OCTL3, ORCTL3, S22AD_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9Y226
- Gene
- SLC22A13
- Ensembl
- ENSG00000172940
- Chromosome
- 3
- Canonical length
- 551 aa
- Protein class
- Metabolic proteins, Predicted membrane proteins, Transporters
OverviewNCBI Gene
This gene encodes a member of the organic-cation transporter family. It is located in a gene cluster with another member of the family, organic cation transporter like 4. The encoded protein is a transmembrane protein involved in the transport of small molecules. This protein can function to mediate urate uptake and is a high affinity nicotinate exchanger in the kidneys and the intestine. [provided by RefSeq, Sep 2008]
Canonical amino-acid sequenceUniProt
551 residues, UniProt reviewed canonical sequence.
>Q9Y226|SLC22A13
1 MAQFVQVLAE IGDFGRFQIQ LLILLCVLNF LSPFYFFAHV FMVLDEPHHC AVAWVKNHTF
61 NLSAAEQLVL SVPLDTAGHP EPCLMFRPPP ANASLQDILS HRFNETQPCD MGWEYPENRL
121 PSLKNEFNLV CDRKHLKDTT QSVFMAGLLV GTLMFGPLCD RIGRKATILA QLLLFTLIGL
181 ATAFVPSFEL YMALRFAVAT AVAGLSFSNV TLLTEWVGPS WRTQAVVLAQ CNFSLGQMVL
241 AGLAYGFRNW RLLQITGTAP GLLLFFYFWA LPESARWLLT RGRMDEAIQL IQKAASVNRR
301 KLSPELMNQL VPEKTGPSGN ALDLFRHPQL RKVTLIIFCV WFVDSLGYYG LSLQVGDFGL
361 DVYLTQLIFG AVEVPARCSS IFMMQRFGRK WSQLGTLVLG GLMCIIIIFI PADLPVVVTM
421 LAVVGKMATA AAFTISYVYS AELFPTILRQ TGMGLVGIFS RIGGILTPLV ILLGEYHAAL
481 PMLIYGSLPI VAGLLCTLLP ETHGQGLKDT LQDLELGPHP RSPKSVPSEK ETEAKGRTSS
541 PGVAFVSSTY FLocalizationUniProt · AlphaFold · HPA
Whether an antibody against SLC22A13 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 12
- Mean surface accessibility (rSASA)
- 0.27
- Highest tissue expression
- 8.4 nTPM
Expression across tissuesHPA
Tissue
- kidney: 8.4 nTPM
- cerebellum: 0.2 nTPM
- esophagus: 0.2 nTPM
- testis: 0.2 nTPM
- bone marrow: 0.1 nTPM
- cervix: 0.1 nTPM
Single-cell type
- neutrophils: 6.9 nCPM
- endometrial glandular cells: 6.3 nCPM
- endometrial luminal cells: 6.1 nCPM
- retinal horizontal cells: 6 nCPM
- cdc: 5.5 nCPM
- respiratory ionocytes: 5.1 nCPM
Immune cell
- T-reg: 0.8 nTPM
- classical monocyte: 0.1 nTPM
- MAIT T-cell: 0.1 nTPM
- memory B-cell: 0.1 nTPM
- memory CD8 T-cell: 0.1 nTPM
- naive B-cell: 0.1 nTPM
Brain region
- cerebral cortex: 5.1 nTPM
- cerebellum: 4.3 nTPM
- white matter: 3.9 nTPM
- amygdala: 3.1 nTPM
- basal ganglia: 3.1 nTPM
- hippocampal formation: 3 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.38
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.11
- DepMap mean gene effect
- -0.09
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- NAD+ biosynthetic process via the salvage pathway
- negative regulation of fatty acid metabolic process
- nicotinate transport
- positive regulation of T cell mediated cytotoxicity directed against tumor cell target
- urate transport
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads SLC22A13 as an antibody target. Whether an autoantibody or antibody against SLC22A13 could matter depends on whether native SLC22A13 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
SLC22A13 is annotated at the cell surface, where native SLC22A13 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label SLC22A13 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...